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OBJECTIVES: Geographic transferability of model-based cost-
effectiveness results across countries can facilitate and shorten
the appraisal process for reimbursement of pharmaceuticals. The
objective of this study was to assess the transferability of a UK
model-based cost-effectiveness analysis of trastuzumab in early
breast cancer in order to obtain a Dutch cost-effectiveness esti-
mate. METHODS: Three checklists published by Welte et al.
(2004), Boulenger et al. (2005) and Urdahl et al. (2006) were
used to assess the transferability of a UK model-based study to
the Dutch setting. RESULTS: The UK study meets the general
knock-out criteria from Welte et al., indicating that in The Neth-
erlands, trastuzumab in early breast cancer is licensed and used in
the same regimen as in the UK model. Applying the checklist by
Boulenger et al produced a high transferability information score
of 93%, indicating an adequate description of model inputs and
transferability to the Dutch setting. The questions by Urdahl
et al. could be answered adequately. The decision was made to
adjust the health state utilities and background mortality. All
UK-prices on resource use were replaced by Dutch unit prices
and updated to 2006. The friction cost method was used to
calculate the costs of productivity loss. The cost inputs and the
risk of cardiac adverse events were varied in one-way sensitivity
analyses. CONCLUSIONS: Overall, transferring the UK-model
structure and adjusting some of the model inputs to the Dutch
setting proved to be an efﬁcient method to obtain a reliable
Dutch estimate for the adjuvant treatment of trastuzumab. The
necessary adjustments were made to the cost-effectiveness study.
Cost-effectiveness calculations, probabilistic sensitivity analysis,
subgroup analyses, one-way sensitivity analysis and value of
information analysis were performed. The outcomes of the mod-
elling are adressed in a separate abstract.
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OBJECTIVES: Tinnitus is a common, chronic health-condition
affecting 10% to 20% of the adult population and especially
hearing impaired individuals. There is no curative therapy for
this condition and treatment is aimed at increasing well-being.
Measurement of health state utilities is an essential element of
CEA in health care. Several studies found that different utility
instruments provide different estimates of the same person’s level
of utility. This study aims to gain insight into differences between
utility measures, by determining the construct validity of EQ-5D
and HUI3 and agreement between both measures in tinnitus
patients. METHODS: Baseline data on EQ-5D and HUI3 of 159
patients in a randomized controlled clinical trial investigating
cost-effectiveness of usual care versus specialized care of tinnitus,
were examined. Agreement was assessed using the intra-class
correlation coefﬁcient (ICC). In absence of a gold standard to
measure health state utility, construct validity was determined by
comparing utility scores for clinical different groups, based on
scores from the Tinnitus Questionnaire. RESULTS: Mean utility
scores for EQ-5D (0.78; sd 0.20) and HUI3 (0.64; sd 0.27) were
different (Wilcoxon Signed Ranks Test, P-value < 0,001), agree-
ment was low to moderate (ICC = 0.40). EQ-5D and HUI3
showed a large correlation (Kendall’s Tau >0.50) between the
dimensions: mobility (EQ-5D) and ambulation (HUI3), anxiety/
depression (EQ-5D) and emotion level (HUI3), and pain/
complaints (EQ-5D) and pain (HUI3). Both utility measures
discriminated between clinically different groups. Groups with
more severe tinnitus had lower utility scores (Kruskal-Wallis
c2 = 8.4, p = 0.015 and c2 = 26.9, p < .001 for EQ-5D and HUI3
respectively). CONCLUSIONS: This study shows that different
utility measures lead to different utility scores among tinnitus
patients. However, both measures are capable of discriminating
between clinically different groups. Further research is conducted
to show responsiveness of both measures to decide which is
preferred in a tinnitus population. Results will be presented at the
conference.
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OBJECTIVES: Assessment of the type of instrument used to
measure health-related quality of life (HRQoL) in published
cancer clinical trials. METHODS: We conducted a keyword
search of Medline for cancer clinical trials, published over last
ﬁve years in English. The inclusion criteria were: adult cancer
patients; assessment of HRQoL as an outcome and at least one
active treatment arm (chemotherapy, radiotherapy, surgery or
some combination). The type of instrument(s) for measuring
HRQoL was identiﬁed. RESULTS: In total, 789 studies were
identiﬁed and 42.6% (336) were included. The reasons for
exclusion were: disease (9.9%), intervention (69.3%), outcome
(12.6%) and study design (8.2%). 42 studies (12.5%) were
placebo-controlled while 201 (59.8%) had active comparator
treatment arm(s). The most common diagnosis was non-small
cell lung cancer (19%). Use of HRQoL instruments was identi-
ﬁed in 211 studies. Of these, speciﬁc instruments were used in
187 studies; including cancer speciﬁc in 182, population speciﬁc
in 4 and signs and symptoms speciﬁc in 1 study. In 103 studies,
disease speciﬁc instruments (modules) were related to particular
type of cancer (studies with breast; colon; brain; prostate; lung;
head & neck; and pancreatic cancers). The EORTC and FACT
questionnaires were widely used. Generic instruments were used
in 23 (6.8%) studies, most common being SF-36 followed by
EuroQol group questionnaire. Both generic as well as speciﬁc
instruments were used in 37 studies. A decrease in the use of
speciﬁc HRQoL instruments was observed (62% in 2003 vs.
33% in 2008). Use of speciﬁc and generic instruments was
similar for trials with active and non-active comparators. CON-
CLUSIONS: Application of generic HRQoL instruments in
cancer clinical trials remains low. Use of speciﬁc HRQoL instru-
ments in these trials appears to have declined in the last ﬁve
years.
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